New HIV Prevention Injection Approved: Hope for Millions

A breakthrough in HIV prevention has emerged with the recent approval of lenacapavir, marketed as Yeztugo, by the Food and Drug Administration (FDA) on June 18, 2023. Developed by Gilead Sciences, this innovative injection represents a significant advancement in the fight against HIV, requiring administration only twice a year. The drug’s approval offers new hope for millions at high risk of infection, particularly in regions heavily impacted by the virus.

The efficacy of lenacapavir is underscored by global Phase 3 trials, which reported nearly 100% effectiveness among the 2,134 participants from diverse regions, including Africa, the United States, Latin America, Europe, and Asia. Notably, none of the participants contracted HIV during the trial period. These promising results bring renewed optimism to communities where access to HIV prevention has been historically limited.

Tatenda Makoni, a Zimbabwean-born medical student at the Medical College of Wisconsin, reflects on the personal significance of this development. Having lost both parents to AIDS before reaching the age of 40, Makoni’s journey into HIV research has been deeply shaped by her childhood experiences. She emphasizes that while the approval of lenacapavir is a crucial step, it is essential to ensure that access to this medication reaches those who need it most.

Challenges in Accessing Life-Saving Treatments

Despite the promising news surrounding lenacapavir, barriers to access remain a pressing concern. In sub-Saharan Africa, women and girls now account for nearly two-thirds of new HIV infections, a stark reminder of the urgent need for effective prevention strategies. Makoni highlights the reality that delays in making such medications available result in new infections and lost lives.

Even before receiving FDA approval, Gilead committed to royalty-free licenses with six generic manufacturers to supply lenacapavir in 120 low- and lower-middle-income countries. Gilead also pledged to provide two million doses at no profit until generics become available. While these initiatives represent meaningful progress, they alone may not be sufficient to eradicate the barriers to access.

Makoni calls for Gilead to expand its licensing agreements beyond income classifications and to invest in regional manufacturing capabilities. This would enable local clinics to provide lenacapavir in partnership with governments and global health agencies. She argues that access to medications should not be limited by arbitrary economic classifications, especially in regions with high HIV burdens.

A Call for Global Action and Political Partnerships

The conversation surrounding HIV prevention often centers on vulnerable groups, particularly adolescent girls and young women who are at the highest risk. Makoni notes that while some express hope for new medicines, skepticism about whether these treatments will actually reach local clinics persists. This skepticism is rooted in a history of uneven rollouts and unmet promises, leaving communities weary and frustrated.

Makoni’s commitment to addressing these issues is fueled by the memories of those lost to HIV, including her parents. As she prepares to become an infectious disease doctor, she carries their legacy into her training, advocating for equitable access to healthcare resources.

The path forward requires not only breakthroughs in medical science but also comprehensive political partnerships that prioritize equity. Global leaders must support broader generic manufacturing initiatives and ensure fair pricing agreements with governments most affected by HIV.

As the fight against HIV continues, the approval of lenacapavir offers a glimmer of hope. Yet, Makoni’s reflections remind us that the true measure of success will be the ability to deliver this life-saving medication to those who need it most, transforming the landscape of HIV prevention and treatment worldwide.